• 1. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 2. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 3. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 4. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

Introduction to (1R,4R)-N1-(4-Fluorobenzyl)cyclohexane-1,4-diamine Hydrochloride (CAS No. 1366386-71-1)

Compound (1R,4R)-N1-(4-Fluorobenzyl)cyclohexane-1,4-diamine hydrochloride, identified by its CAS number 1366386-71-1, is a meticulously crafted molecule that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to a class of bisamine derivatives, characterized by its chiral cyclohexane backbone and a fluorobenzyl substituent at the N1 position. The stereochemistry of this molecule, specifically the (1R,4R) configuration, plays a crucial role in its biological activity and pharmacological properties.

The synthesis of (1R,4R)-N1-(4-Fluorobenzyl)cyclohexane-1,4-diamine hydrochloride involves a series of well-planned chemical transformations that highlight the expertise of modern synthetic organic chemistry. The introduction of the fluorobenzyl group at the N1 position not only imparts unique electronic properties to the molecule but also enhances its binding affinity to biological targets. This modification is particularly significant in drug design, as fluorine atoms are known to improve metabolic stability and bioavailability of pharmaceutical compounds.

In recent years, there has been a growing interest in the development of chiral bisamine compounds for their potential applications in treating various diseases. The diamine moiety in (1R,4R)-N1-(4-Fluorobenzyl)cyclohexane-1,4-diamine hydrochloride offers multiple interaction points with biological targets, making it a versatile scaffold for drug discovery. Studies have demonstrated that such compounds can exhibit potent activity against a range of therapeutic targets, including enzymes and receptors involved in metabolic disorders and inflammatory diseases.

One of the most compelling aspects of this compound is its potential in the development of novel therapeutics for neurological disorders. The chiral environment provided by the cyclohexane ring and the fluorobenzyl group can influence the molecule's ability to cross the blood-brain barrier, which is crucial for treating central nervous system (CNS) diseases. Recent research has shown that similar bisamine derivatives have shown promise in preclinical studies for conditions such as Alzheimer's disease and Parkinson's disease.

The hydrochloride salt form of (1R,4R)-N1-(4-Fluorobenzyl)cyclohexane-1,4-diamine hydrochloride enhances its solubility and bioavailability, making it more suitable for formulation into pharmaceutical products. This property is particularly important for oral administration, where solubility directly impacts absorption rates and therapeutic efficacy. The salt form also improves stability during storage and transportation, ensuring that the compound remains effective throughout its shelf life.

The fluorine atom at the 4-position of the benzyl group is a key feature that contributes to the unique properties of this compound. Fluorine substitution is a common strategy in drug design due to its ability to modulate electronic effects and steric interactions. In (1R,4R)-N1-(4-Fluorobenzyl)cyclohexane-1,4-diamine hydrochloride, the fluorine atom enhances binding affinity by participating in hydrogen bonding and dipole interactions with biological targets. This has been observed in various fluoro-substituted compounds that have shown improved pharmacokinetic profiles compared to their non-fluorinated counterparts.

Recent advancements in computational chemistry have enabled researchers to predict the biological activity of molecules like (1R,4R)-N1-(4-Fluorobenzyl)cyclohexane-1,4-diamine hydrochloride with greater accuracy before they are synthesized. Molecular modeling techniques have been used to identify potential binding pockets on target proteins and simulate how different conformations of the compound can interact with these sites. These simulations have guided the optimization process and led to more efficient development pipelines.

The pharmacological profile of this compound has been extensively studied in vitro and in vivo. Initial cell-based assays have revealed that it exhibits potent inhibitory activity against several enzymes relevant to metabolic diseases. For instance, studies have shown that it can inhibit xanthine oxidase and monoamine oxidase enzymes at concentrations comparable to known therapeutic agents. This makes it a promising candidate for further development into treatments for conditions such as gout and depression.

In addition to its enzymatic activity, (1R,4R)-N1-(4-Fluorobenzyl)cyclohexane-1,4-diamine hydrochloride has also shown potential as an anti-inflammatory agent. In preclinical models of inflammation, this compound has demonstrated ability to modulate key signaling pathways involved in immune responses. By targeting specific inflammatory mediators, it may offer a new approach to treating chronic inflammatory diseases without causing significant side effects associated with traditional anti-inflammatory drugs.

The synthesis of enantiomerically pure compounds like (1R,4R)-N1-(4-Fluorobenzyl)cyclohexane-1,4-diamine hydrochloride is challenging but essential for achieving optimal pharmacological outcomes. Chiral purity is critical because even small amounts of impurities can significantly alter biological activity due to differences in stereoselective interactions with biological targets. Advanced synthetic techniques such as asymmetric catalysis have been employed to ensure high enantiomeric purity during production.

The future prospects for this compound are promising as ongoing research continues to uncover new therapeutic applications. Researchers are exploring its potential use in treating not only metabolic and neurological disorders but also cancer and infectious diseases. The versatility of its molecular framework allows for further modifications that could enhance its efficacy or expand its spectrum of activity.

In conclusion, (1R,4R)-N1-(4-Fluorobenzyl)cyclohexane-1,4-diamine hydrochloride (CAS No. 1366386-71-1) represents an innovative approach in pharmaceutical chemistry with significant potential for developing novel therapeutics. Its unique structural features combined with promising preclinical results make it a valuable asset in ongoing drug discovery efforts aimed at addressing unmet medical needs.

• 1353987-21-9(N1,N4-Bis(3-fluorobenzyl)cyclohexane-1,4-diamine)
• 356531-67-4(N-(4-Fluorobenzyl)cyclohexanamine)
• 85952-73-4(N-Cyclopentyl-p-fluorobenzylamine)
• 1353954-71-8(N1-(3-Fluorobenzyl)cyclohexane-1,2-diamine hydrochloride)
• 1318762-87-6(N1,N2-Bis(4-fluorobenzyl)cyclohexane-1,2-diamine)
• 58048-60-5(Benzenemethanamine, 4-fluoro-N-(1-methylhexyl)-, hydrochloride)
• 1261230-85-6(N-(4-Fluorobenzyl)-N-methylpiperidin-4-amine hydrochloride)
• 1353946-54-9(N1-(4-Fluorobenzyl)cyclohexane-1,4-diamine hydrochloride)
• 1353959-43-9(N1-(2-Fluorobenzyl)cyclohexane-1,4-diamine hydrochloride)
• 500221-71-6(N-[(3-fluorophenyl)methyl]cyclohexanamine)